ProKidney Corp. (PROK NASDAQ) stock market data APIs
$2.1945
-0.12(-5.5%)
as of February 19, 2026
Try our APIs with
free plan!
ProKidney Corp. Financial Data Overview
Price chart is built with
Anychart
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Prev. Close
2.1945
Open
2.0767
High
2.2089
Low
2.0269
52 wk Range
0.4603-5.95
Market Cap
635 M
Shares Outstanding
142 M
Revenue
744 K
EPS
-0.12
Beta
1.817
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ProKidney Corp. data using free add-ons & libraries
Get ProKidney Corp. Fundamental Data
ProKidney Corp. Fundamental data includes:
- Net Revenue: 744 K
- EBITDA: -164 576 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.1461
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ProKidney Corp. News
New
3 Promising Penny Stocks With At Least $600M Market Cap
As U.S. stock indexes have started February on a high note, with the Dow Jones Industrial Average and S&P 500 showing impressive gains, investors are closely watching for opportunities in various mark...
3 Penny Stocks With Market Caps Under $700M
Major U.S. stock indexes have recently pulled back after setting fresh all-time highs, reflecting a complex economic landscape influenced by geopolitical events and fluctuating oil prices. In this cli...
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chr...
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright
ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analy...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
